Fear today
As of 01/31/2025 03:59 pm
- 52 weeks
- 153.58 dollars
▼
207.32 dollars
- Profit
- 3.57 %
- P/E ratio.
- 63.85
- The target price
- 205.00 dollars
Exhausted Nyse: abbv It is a high -quality pharmaceutical company and a growing profit distributions with strong growth expectations: Now is the time to download on stocks. Fears of patent cliffs in Hemira, with Skyrizi, Rinvoq, and a variety of products of products that gain traction. Among the critical details of the Q4 and the end of the F2024 is that Humira sales decreased by two strong numbers and are expected to be weakened in 2025. However, Rinvoq and Skyrizi rose by 46 % and 58 %, respectively, respectively, more than the coup compensation.
The company is looking forward, the company reaffirmed the expectations of an annual growth rate of high numbers at least during the next four years, the expectations that put this high diamond in less than 10 times by 2030, an opportunity of very deep value to pass.
Abbvie acquires traction in the post -Homra world
Investors who are concerned about the longevity of a lap life in the post -Homra world can put their concerns to rest. Q4 results, strong, including 5.6 % growth, which outperformed consensus expectations. Growth was seen in most sectors with neuroscience, which leads to 20 % and beauty that is 5.2 %. Immunology, the primary part, grew, approximately 5 % under the influence of its new films, while oncology, a critical growth path, increased by 12 %.
Mixed news is mixed due to the cutting of the acquired IP/RD teacher. The company published the loss of the principles of acceptable accounting in general and the modified contraction, leaving the arrow’s profit at $ 2.16 and less than expectations. However, the profits and cash flow are still strong enough to maintain the health of the public budget, capital returns, and long -term expectations. It is expected that the impact of the search and development features will affect advanced results, with the progress of pipelines, which leads to the next round of important versions.
The guidance is the reason that the share price will rise in 2025. The first F2025 guidelines are strong, with a expectation of $ 12.22 in the modified EPS in the mid -point range. This increases by 18 % of Marketbeat consensus reported at the time of release, but it does not include possible features, so it may not be comparable directly. However, assuming that AIP/RD features are equal to 2024 in 2025, the guidance is still better than consensus and positive for investors.
Analysts support ABBVIE share in 2025
ABBVIE stock forecast today
205.00 dollars
Moderate purchase
Based on 24 analyst classification
| High expectations | 225.00 dollars |
|---|---|
| Average expectations | 205.00 dollars |
| Low expectations | 180.00 dollars |
ABBVIE shares details details
Feelings trends for analysts are strong, with coverage significantly high in the second half of 2024, the target price height, and a two -numbered head height. The number of analysts covering the share increased by 60 % to 24 in H2 2024, which is important due to the investment dollars they represent and flow through its coverage. They evaluate stocks as a mild purchase and see them rising to $ 205 or higher by the end of the year. Other background wind institutions provide the market, buying the balance every quarter since 2022 and buying more than twice the sale.
The capital’s return is among the reasons that make my narratives such shares. Growth, cash flow and public budget expectations support health profit distributions of about 60 % of profits and more than 3.5 % in return, with shares trading near critical support levels.
Abbvie: Recovery in the operating mode, which is a possible new height this year
The ABBVIE market responded strongly to 5 % progress in the pre -market trade. This step extends to a recovery that started earlier this week and confirms strong support at the level of $ 170, in line with the direction follow -up signal. Stochastic and MACD indicators gather from the signal, as they are in line with the sales market in the direction of ascension, and are ready for the next ups of the upper upward. ABBV shares price may advance to the level of $ 200 and set the highest new level in this scenario, but first, it must cross $ 186.50 and close the gap that was formed in late 2024.
Before you think about Abbvie, you will want to hear this.
Marketbeat follows the best research analyst at Wall Street, the best performance in Wall Street and the stocks they recommend to their customers on a daily basis. Marketbeat has selected the five shares whose senior analysts whispered quietly to their customers to buy now before wiping the broader market … and ABBIE was not in the list.
While ABBVIE currently has a “moderate purchase” classification among analysts, analysts from the top rankings believe that these five stocks buy better.
Show the five stocks here
Enter your email address and we will send you the Marketbeat menu for the 10 best shares you own in 2025 and why should you be in your wallet.
